Tafolecimab

Phase 2

Innovent Biologics Inc/ADR (IVBXF)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

IVBXFPhase 2$24.9B

Tafolecimab Phase 2 Est. Readout

Tafolecimab• Extensive-stage Small Cell Lung Cancer (ES-SCLC)40

Q3 2027~QConfirmed

CT.gov

00%

Competitive Landscape

0 competitors in Extensive-stage Small Cell Lung Cancer (ES-SCLC)

View Full Landscape

Drug Information

Target Indication

Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Clinical Trial

NCT07061535

Last updated: 10/3/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

IVBXF

Innovent Biologics Inc/ADR

Biotechnology•North America•NASDAQ

Related Pipeline

Aflibercept OphthalmicPhase 3

Neovascular Age-related Macular Degeneration

FebuxostatPhase 3

Gout

Investigator's choice of therapyPhase 3

Colorectal Cancer

PicankibartPhase 3

Plaque Psoriasis

IBI301 plus CHOPPhase 3

Diffuse, Large B-Cell, Lymphoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts